All Posts
Comprehensive review on the management of pharmaceutical and recreational drug poisoning
1 Dec, 2020 | 08:21h | UTCManagement of pharmaceutical and recreational drug poisoning – Annals of Intensive Care
Opinion: How Prestige Journals Remain Elite, Exclusive and Exclusionary. “by announcing a €9,500 price tag, Nature has failed to enact their own diversity and inclusion pledge”
1 Dec, 2020 | 08:22h | UTCHow Prestige Journals Remain Elite, Exclusive And Exclusionary – Forbes
See also: For €9500, Nature journals will now make your paper free to read
Opinion: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data
1 Dec, 2020 | 08:13h | UTC
Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
1 Dec, 2020 | 08:08h | UTCCommentary: Gout drug Colchicine to be tested as COVID-19 treatment in UK trial – Reuters
Critically ill patients with COVID-19: A narrative review on prone position
1 Dec, 2020 | 08:07h | UTCCritically Ill Patients with COVID-19: A Narrative Review on Prone Position – Pulmonary Therapy
The Ioannidis affair: A tale of major scientific overreaction
1 Dec, 2020 | 08:10h | UTCThe Ioannidis Affair: A Tale of Major Scientific Overreaction – Scientific American
The COVID science wars: Shutting down scientific debate is hurting the public health
1 Dec, 2020 | 08:11h | UTCThe COVID Science Wars – Scientific American
Report: SARS-CoV-2 setting-specific transmission rates. Households showed the highest transmission rates (21.1%). Asymptomatic infections do occur but much less efficiently than symptomatic infection.
30 Nov, 2020 | 01:01h | UTCFull report: SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis – Imperial College London
AstraZeneca vaccine most attractive option for Africa, says WHO – Astra Zeneca CEO says company will run new trial to test more efficient dose
1 Dec, 2020 | 08:05h | UTC
No evidence for increased transmissibility from mutations in SARS-CoV-2
30 Nov, 2020 | 01:06h | UTCCommentaries: Mutations not making coronavirus able to spread more rapidly -study – Reuters AND Covid-19 has NOT become more infectious: Study identifies almost 13,000 coronavirus mutations but none – including the dominant D614G strain – made it better at spreading – Daily Mail
Study: Fewer than 10% of people in the US had detectable SARS-CoV-2 antibodies as of September 2020
30 Nov, 2020 | 01:00h | UTCEstimated SARS-CoV-2 Seroprevalence in the US as of September 2020 – JAMA Internal Medicine
Commentaries: Less than 10% of Americans had COVID by September, study finds – CIDRAP AND Antibodies, Immunity, and COVID-19 – JAMA Internal Medicine AND Covid-19: Nationwide SARS-CoV-2 Seroprevalence Remains Low – Physician’s Weekly
Commentary on Twitter
.@CDCgov tested more than 177,000 serum samples across 52 sites (50 states, DC, and Puerto Rico) between July 27 and September 24 for #SARSCoV2 antibodies. The study found that, in 45 US sites, less than 10% of samples had evidence of previous infection https://t.co/U4hp68fFAx
— JAMA Internal Medicine (@JAMAInternalMed) November 24, 2020
Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany estimated at 0.36%
30 Nov, 2020 | 01:02h | UTCInfection fatality rate of SARS-CoV2 in a super-spreading event in Germany – Nature Communications
Meta-analysis of statins for primary prevention: 100 adults (aged 50-75 years) without known cardiovascular disease would have to be treated for 2.5 years to prevent 1 major adverse cardiovascular event
30 Nov, 2020 | 00:56h | UTCEvaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary: Time to Benefit of Statins for Primary Prevention of Cardiovascular Events – American College of Cardiology
Commentary on Twitter
It takes 2.5 years for the benefits of #statins to be seen. Frail older adults with life expectancy <2.5 years may be more likely to be harmed than helped by statins https://t.co/jbdW7bXopt
— JAMA Internal Medicine (@JAMAInternalMed) November 16, 2020
Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally
30 Nov, 2020 | 00:59h | UTCOriginal study: Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis – medRxiv
Opinion – Covid-19: controversial trial may actually show that masks protect the wearer
30 Nov, 2020 | 00:58h | UTCCovid-19: controversial trial may actually show that masks protect the wearer – The BMJ Opinion
Original study and commentaries: Randomized trial suggesting mask use does not protect the wearer from Covid-19 sparks controversy
Related commentary on Twitter (thread – click for more)
1/
My appraisal of the Danish mask study (DANMASK-19): This was a negative trial – masks were not shown to prevent #COVID19.Could chance or bias make this outcome more likely?
Does this mean we don’t need to wear masks?Let’s take a deeper look.#HowIReadThisPaper
(Thread) pic.twitter.com/bAUuajgtaI
— Rahul Ganatra (@rbganatra) November 28, 2020
For €9500, Nature journals will now make your paper free to read
30 Nov, 2020 | 00:49h | UTCFor €9500, Nature journals will now make your paper free to read – Science
News release: Nature journals reveal terms of landmark open-access option
State of the art review: Advances in the diagnosis and management of gastroesophageal reflux disease
30 Nov, 2020 | 00:52h | UTCAdvances in the diagnosis and management of gastroesophageal reflux disease – The BMJ (free for a limited period)
Randomized trial: Laryngeal mask airway is safe but not superior to face-mask ventilation for resuscitation of asphyxiated newborn infants
27 Nov, 2020 | 08:43h | UTC
Editor’s Choice: The curious case of the Danish mask study
30 Nov, 2020 | 00:56h | UTCEditor’s Choice: The curious case of the Danish mask study – The BMJ
Original study and commentaries: Randomized trial suggesting mask use does not protect the wearer from Covid-19 sparks controversy
Randomized trial: Intravenous iron is superior to oral iron for the treatment of anemia in women after childbirth in a low-income setting
27 Nov, 2020 | 08:41h | UTC
Commentary on Twitter
In a randomised trial in Tanzania, intravenous ferric carboxymaltose proved safe and better than oral iron at achieving haemoglobin normalisation (>115 g/L) at 6 weeks after childbirth in women with iron deficiency anaemia https://t.co/F5sau45dwL pic.twitter.com/qqa8cGbMqZ
— The Lancet Global Health (@LancetGH) November 25, 2020
Systematic review: Peripheral nerve blocks for hip fractures reduce pain on movement, risk of acute confusional state, risk of chest infection, and time to first mobilization
27 Nov, 2020 | 08:37h | UTCPeripheral nerve blocks for hip fractures in adults – Cochrane Library
New WHO guidelines on physical activity and sedentary behavior – Every move counts towards better health
27 Nov, 2020 | 08:45h | UTCWHO guidelines on physical activity and sedentary behaviour – World Health Organization
News release: Every move counts towards better health – says WHO
Commentaries: Aim to exceed weekly recommended physical activity level to offset health harms of prolonged sitting – BMJ AND You only need 30 to 40 minutes of exercise per day to ‘offset’ sitting at your desk all day, new analysis finds – Business Insider AND Physical activity guidelines 2020: comprehensive and inclusive recommendations to activate populations – The Lancet
Commentary on Twitter
Launched today new 2020 WHO Guidelines on PA & Sedentary behaviour. Check out WHO website for summary in 6 UN languages. Take home message #EveryMoveCounts #BeActive Thanks to everyone who helped to produce this new global policy @WHO @ISPAH @BJSM_BMJ pic.twitter.com/tersZkMj3i
— fiona bull (@fiona_bull) November 25, 2020
Study ranks the most effective non-pharmaceutical interventions for reducing COVID-19 spread
27 Nov, 2020 | 08:36h | UTCRanking the effectiveness of worldwide COVID-19 government interventions – Nature Human Behaviour
Commentary: Epidemiology: Assessing non-pharmaceutical interventions in reducing COVID-19 spread – Nature Asia
Long Covid: Comprehensive health assessment three months after recovery from acute COVID-19 revealed problems in several health domains in a substantial number of patients
27 Nov, 2020 | 08:33h | UTC
Covid-19: 15% of people responsible for 80% of secondary infections
27 Nov, 2020 | 08:27h | UTCTransmission heterogeneities, kinetics, and controllability of SARS-CoV-2 – Science
Commentary: What we can learn from contact tracing an entire province – Ars Technica
Commentary on Twitter
Study of 1,178 #COVID19 cases & their 15,648 contacts in Hunan, China. Just 15% of people were responsible for 80% of secondary infections.
Children were less likely to be infected than young to middle-aged adults, but infectiousness didn’t differ by age.https://t.co/PYaj9pbSJo pic.twitter.com/mREh5wWkKd
— Dr Zoë Hyde (@DrZoeHyde) November 26, 2020